Anne Feaster
Adult Health · Langhorne, PANPI 1932259652
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.5% of the total across 633 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 9.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $4,277 and has fallen 57.1% since, to $1,836 in 2025. Among adult health clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 633 payments — averaging $24.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- E.r. Squibb & Sons, L.L.C.$1K
- Novartis$1K
- Daiichi Sankyo Inc.$728
- Incyte Corporation$627
- AstraZeneca$613
- plus $10K from 54 others
What the payments were for
- Food & beverage$14,66897%
- Education$5293%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,197 in reported general payments places this provider in the 95th percentile of 899 adult health providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 66 | $948,813 |
| CalquenceAcalabrutinib Maleate | 43 | $648,050 |
| IbrancePalbociclib | 29 | $434,944 |
| TasignaNilotinib Hcl | 19 | $374,361 |
| Lenalidomide | 20 | $365,826 |
| RevlimidLenalidomide | 21 | $347,169 |
| JakafiRuxolitinib Phosphate | 19 | $322,235 |
| PomalystPomalidomide | 14 | $306,712 |
| VerzenioAbemaciclib | 15 | $220,210 |
| ImbruvicaIbrutinib | 19 | $197,212 |
| TagrissoOsimertinib Mesylate | 11 | $186,734 |
| EliquisApixaban | 187 | $158,226 |
| VenclextaVenetoclax | 12 | $82,423 |
| XareltoRivaroxaban | 63 | $64,549 |
| Imatinib Mesylate | 20 | $53,171 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $498 | $948,81366 claims |
| AstraZenecaCalquence, Tagrisso | $613 | $834,78554 claims |
| PfizerIbrance, Eliquis | $420 | $593,170216 claims |
| NovartisTasigna | $1,004 | $374,36119 claims |
| Bristol Myers SquibbRevlimid | $282 | $347,16921 claims |
| Incyte CorporationJakafi | $627 | $322,23519 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $1,079 | $306,71214 claims |
| Lilly USA, LLCVerzenio | $256 | $220,21015 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $357 | $197,21219 claims |
| AbbVieVenclexta | $393 | $82,42312 claims |
| Johnson & JohnsonXarelto | $1,442 | $64,54963 claims |
| Beigene USA, Inc.Brukinsa | $19 | $42,26011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 899 adult health providers in Pennsylvania.
Other adult health in Langhorne
- Marika HartmanLanghorne$13K
- Kelly WelwoodLanghorne$8K
- Beth SandyPhiladelphia$924K
- Jennifer MondilloSchwenksville$396K
- Diane NewmanPhiladelphia$343K
- Elizabeth FaustDouglassville$342K
- Abigail SmithPhiladelphia$302K
- Jean CainAllentown$214K
- Jennifer KeeleyWexford$97K
- Debra EvansFarrell$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.